Recurrence and Tailoring Radiotherapy Following Neoadjuvant Chemotherapy
Eleftherios Mamounas, MD, MPH, discusses locoregional recurrence and tailoring radiotherapy following neoadjuvant chemotherapy.
Clinical Pearls
Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses locoregional recurrence and tailoring radiotherapy following neoadjuvant chemotherapy.
- Researchers are trying to understand whether the response and tumor subtype of patients treated with neoadjuvant chemotherapy can help to tailor the use of radiotherapy afterwards.
- Though the data from this analysis do not provide a definitive answer, they help researchers understand that these patients had low rates of recurrence and tailoring radiotherapy is possible. Trials are in progress to test this concept.
<<<
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
